Press

Nucleus CEO Publishes “Letter from the Captain,” Summarizes Q1 Progress

Apr 11 • 9 min read

Psychedelic Invest’s parent company, Nucleus Holding, Inc. is slated to close its crowdfunding campaign this month. Over on the campaign page at Wefunder, Nucleus CEO Logan Lenz published an update that summarizes how he sees Nucleus positioned amidst the current psychedelics industry. The contents of the letter are also posted below. Hello, I’m Logan, the…

Numinus Launches new Clinic Licensing Platform, the Numinus Network, to Accelerate Expansion

Apr 11 • 4 min read

Numinus Wellness Inc. (TSX: NUMI / OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched a new clinic licensing model, named the Numinus Network, offering independent practitioners the opportunity to own and operate their own clinic under the trusted Numinus Wellness brand through a licensing…

Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement

Apr 11 • 3 min read

Mydecine Innovations Group Inc. (NEO: MYCO / OTC: MYCOF / FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the “Subscription…

COMPASS Pathways to participate in upcoming 22nd Annual Needham Virtual Healthcare Conference

Apr 11 • 2 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the 22nd Annual Needham Virtual Healthcare Conference at 9:30 am ET on April 19, 2023. A live audio webcast of the presentation will be accessible from the “Events”…

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

Apr 11 • 4 min read

Bright Minds Biosciences Inc. (CSE:DRUG / NASDAQ:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Alex Vasilkevich, Bright Minds’ Scientific Officer, will present at the 20th International Meeting of the International Society for Serotonin Research (ISSR). The ISSR, a nonprofit founded in 1987,…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441